Updates are available Addendum dated 2025-09-05

Article History

Received: 20 November 2023

Accepted: 13 March 2024

First Online: 22 March 2024

Change Date: 5 September 2025

Change Type: Update

Change Details: Following publication of this article, the authors identified errors in the originally published source data due to idiosyncrasies in how some follow-up dates were coded in the clinical trials database. The original data have been audited and the Source Data and Supplementary Information files are now revised alongside this article. A linked Addendum provides discussion of the error and further review of the data.

Competing interests

: C.L.S. has the following disclosures: Research support to the University of Virginia from Celldex (funding, drug), Glaxo-Smith Kline (funding), Merck (funding, drug), 3 M (drug), Theraclion (device staff support); Funding to the University of Virginia from Polynoma for PI role on the MAVIS Clinical Trial; Funding to the University of Virginia for roles on Scientific Advisory Boards for Immatics and CureVac. Also, C.L.S. has received licensing fee payments through the UVA Licensing and Ventures Group (UVA LVG) for patents for peptides used in these cancer vaccines. Patents relevant to peptides in this vaccine include United States Patent # 6,660,276; 6,558,671; and 7,019,112; however, the terms of those patents have expired. He holds other patents for peptides in melanoma vaccines (US Patent number US 9,345,755 B2, plus one submitted, all managed by UVA LVG. N.B.H. does not have any conflicts relative to melanoma research, but has attended advisory board meetings for Eisai, BMS, Merck, Exelixis in the past 2 years. M.I.R. has relationships with Merck (US Global Advisory Board Member (<$10,000) and Consultant (Travel Expenses) and Amgen (Consultant (travel expenses) and Support to the institution for clinical research support). There are no other disclosures or competing interests for the other authors.